Clinical Trial Update: Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluated the pharmacokinetics and safety of brimonidine tartrate 0.025% ophthalmic solution for ocular hyperemia; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conjunctival Hyperemia

Drugs mentioned

• Brimonidine tartrate ophthalmic solution 0.025% (Brimonidine tartrate)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Hyperemia | Phase 1 | Status: COMPLETED